Design Issues in Selected Recent or Ongoing Stroke Trials

  • M. Schwaninger
  • P. Ringleb
  • W. Hacke
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 47)

Abstract

The basic science of cerebral ischemia is complex and involves multiple systems. As reviewed elsewhere, hypoperfusion, excitotoxicity, inflammation, and apoptosis are the main disease mechanisms that are tackled by pharmacological interventions. A large number of agents and strategies has been developed to change the pathophysiological cascade. While it has been a rather easy task to find agents that would work in the experimental setting, translation into the clinic has been a major problem. After more than two decades of dedicated clinical trials, only a single agent, rt-PA, has been approved by national agencies for routine use. This review will discuss pitfalls of prior clinical trials and the promise of upcoming strategies in clinical testing.

Keywords

Placebo Toxicity Ischemia Heparin Neurol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The Abciximab in Ischemic Stroke Investigators (2000) Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31:601–609CrossRefGoogle Scholar
  2. Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U, Auffarth GU, Grau AJ, Green F, Grond-Ginsbach C, Schwaninger M (2003) Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 34:1864–1870PubMedCrossRefGoogle Scholar
  3. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMedCrossRefGoogle Scholar
  4. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526PubMedCrossRefGoogle Scholar
  5. Bonita R, Beaglehole R (1988) Recovery of motor function after stroke. Stroke 19:1497–1500PubMedCrossRefGoogle Scholar
  6. Brott T, Adams HP Jr, Olinger CP, Marier JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870PubMedCrossRefGoogle Scholar
  7. Caro JJ, Huybrechts KF (1999) Stroke treatment economic model (STEM): predicting long-term costs from functional status. Stroke 30:2574–2579PubMedCrossRefGoogle Scholar
  8. Dawson DA, Wadsworth G, Palmer AM (2001) A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res 892:344–350PubMedCrossRefGoogle Scholar
  9. Di Napoli M, Papa F, Bocola V (2001a) C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32:917–924PubMedCrossRefGoogle Scholar
  10. Di Napoli M, Papa F, Bocola V (2001b) Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32: 133–138PubMedCrossRefGoogle Scholar
  11. Elting JW, Suiter GA, Kaste M, Lees KR, Diener HC, Hommel M, Versavel M, Teelken AW, De Keyser J (2002) AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 33:2813–2818PubMedCrossRefGoogle Scholar
  12. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD (1998) Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 50:883–890PubMedCrossRefGoogle Scholar
  13. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 282:2003–2011PubMedCrossRefGoogle Scholar
  14. Grotta J (2001) Combination therapy stroke trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 12:258–263PubMedCrossRefGoogle Scholar
  15. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, Meier D (1998) Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke 29:2073–2075PubMedCrossRefGoogle Scholar
  16. Hacke W, Kaste M, Olsen TS, Bogousslavsky J, Orgogozo JM, Committee ftEE (2000) Acute treatment of ischemic stroke. Cerebrovasc Dis 10 [Suppl 3]:22–33PubMedCrossRefGoogle Scholar
  17. Herrmann O, Tarabin V, Suzuki S, Attigah N, Prinz S, Schneider A, Coserea I, Monyer H, Brombacher F, Schwaninger M (2003) Regulation of body temperature and neuroprotection by endogenous interleukin-6 in focal cerebral ischemia. J Cereb Blood Flow Metab 23:406–415PubMedCrossRefGoogle Scholar
  18. Jonas S, Aiyagari V, Vieira D, Figueroa M (2001) The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke. The predictive value of animal models. Ann N Y Acad Sci 939:257–267PubMedCrossRefGoogle Scholar
  19. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A (1995) Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 333:1588–1593PubMedCrossRefGoogle Scholar
  20. Kidwell CS, Liebeskind DS, Starkman S, Saver JL (2001) Trends in acute ischemic stroke trials through the 20th century. Stroke 32:1349–1359PubMedCrossRefGoogle Scholar
  21. Lees KR (2002) Neuroprotection is unlikely to be effective in humans using current trial design: an opposing view. Stroke 33:308–309PubMedGoogle Scholar
  22. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T (2001) The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology 57:1199–1205PubMedCrossRefGoogle Scholar
  23. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E (2002) Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 33:122–128PubMedCrossRefGoogle Scholar
  24. Muir KW (2002) Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 33:1545–1550PubMedCrossRefGoogle Scholar
  25. NINDS rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587CrossRefGoogle Scholar
  26. Rankin J (1957) Cerebral vascular accidents in patients over the age of 60. Scott Med J 2:200–215PubMedGoogle Scholar
  27. Reith J, Jorgensen H, Pedersen P, Nakayama H, Raaschou H, Jeppesen L, Olsen T (1996) Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 347:422–425PubMedCrossRefGoogle Scholar
  28. Samsa GP, Matchar DB (2001) Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 32:669–674PubMedCrossRefGoogle Scholar
  29. Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, Heiland S, Schwab S, Pohlers O, Ryssel H, Orakcioglu B, Sartor K, Hacke W (2001) Stroke magnetic resonance imaging within 6 h after onset of hyperacute cerebral ischemia. Ann Neurol 49:460–469PubMedCrossRefGoogle Scholar
  30. Schellinger PD, Fiebach JB, Hacke W (2003) Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 34:575–583PubMedCrossRefGoogle Scholar
  31. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE (2000) Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 283:2395–2403PubMedCrossRefGoogle Scholar
  32. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607PubMedCrossRefGoogle Scholar
  33. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R (2000) Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 48:713–722PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • M. Schwaninger
  • P. Ringleb
  • W. Hacke

There are no affiliations available

Personalised recommendations